AllSight
Companies · TBPH · Pharmaceutical Preparations

Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma, Inc. (TBPH) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Theravance Biopharma, Inc. (TBPH) stock — financials & valuation

Key numbers for Theravance Biopharma, Inc. (TBPH): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 53/100 — a percentile rank of Theravance Biopharma, Inc.’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.

Gross margin100.0%
Operating margin-46.2%
Net margin-28.2%
ROIC-47.2%
Revenue growth-41.7%

Independent of the events above — derived from Theravance Biopharma, Inc.’s own financial statements and shown as context, never as advice.

Sep 23, 2026$929M acquisition
Theravance merger closes, delisting begins as ampreloxetine upside shifts to CVR
Sep 10, 2026Proxy supplement
Theravance adds merger disclosures as shareholder lawsuits pile up before Sept. 18 vote
Aug 25, 2026FDA path remains open
Theravance keeps ampreloxetine alive after CYPRESS miss, but FDA demands another pivotal trial
Aug 10, 2026
YUPELRI grew, but revenue missed consensus amid deal and restructuring costs
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact